CAP-002

N/A

Report date: 2026/04/08 15:42:15
First In Class

Base Information

Drug NameCAP-002
Drug Alias NameCAP-002
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionSyntaxin-binding protein 1 gene transference
TargetsSyntaxin-binding protein 1
Therapy Area/IndicationsDevelopmental and epileptic encephalopathyEpilepsy
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCapsida Biotherapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCapsida Biotherapeutics Inc
Active IndicationsN/A
Inactive IndicationsDevelopmental and epileptic encephalopathyEpilepsy

Other Information

ATC CodeN/A
Related LinksN/A